Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

CABA | Cabaletta Bio Inc

IndexRUT P/E- EPS (ttm)-1.74 Insider Own22.47% Shs Outstand39.80M Perf Week0.48%
Market Cap587.85M Forward P/E- EPS next Y-1.71 Insider Trans-0.73% Shs Float30.86M Perf Month6.80%
Income-57.46M PEG- EPS next Q-0.39 Inst Own73.08% Short Float / Ratio10.17% / 5.18 Perf Quarter21.86%
Sales0.00M P/S- EPS this Y8.73% Inst Trans-22.45% Short Interest3.14M Perf Half Y83.48%
Book/sh4.38 P/B3.38 EPS next Y-3.80% ROA-40.09% Target Price25.50 Perf Year2200.26%
Cash/sh4.43 P/C3.33 EPS next 5Y- ROE-42.61% 52W Range0.64 - 19.34 Perf YTD59.68%
Dividend- P/FCF- EPS past 5Y-180.48% ROI-32.62% 52W High-23.63% Beta2.49
Dividend %- Quick Ratio20.94 Sales past 5Y0.00% Gross Margin- 52W Low2207.81% ATR1.31
Employees60 Current Ratio20.94 Sales Q/Q- Oper. Margin0.00% RSI (14)48.91 Volatility9.03% 9.42%
OptionableYes Debt/Eq0.02 EPS Q/Q16.97% Profit Margin- Rel Volume3.21 Prev Close14.80
ShortableYes LT Debt/Eq0.01 EarningsAug 10 BMO Payout- Avg Volume605.22K Price14.77
Recom1.00 SMA20-4.03% SMA505.36% SMA20032.39% Volume1,943,634 Change-0.20%
Date Action Analyst Rating Change Price Target Change
Sep-05-23Initiated Citigroup Buy $22
Jul-18-23Initiated Guggenheim Buy $34
Jan-27-23Upgrade Morgan Stanley Equal-Weight → Overweight $3 → $16
Aug-30-22Downgrade Morgan Stanley Overweight → Equal-Weight $15 → $3
Dec-08-21Initiated Wells Fargo Overweight $17
Oct-19-21Resumed Morgan Stanley Overweight $20
Jun-30-21Initiated Mizuho Buy $22
Jan-08-21Initiated Chardan Capital Markets Buy $21
Oct-13-20Initiated H.C. Wainwright Buy $20
Nov-19-19Initiated Morgan Stanley Overweight $19
Nov-19-19Initiated Cowen Outperform
Oct-02-23 09:14AM
Oct-01-23 11:00AM
Sep-25-23 08:50AM
Sep-19-23 08:00AM
02:00PM Loading…
Sep-01-23 02:00PM
Aug-31-23 09:55AM
Aug-30-23 08:00AM
Aug-25-23 10:13AM
Aug-23-23 08:50AM
Aug-22-23 08:00AM
Aug-15-23 01:46PM
Aug-10-23 07:00AM
10:00AM Loading…
Aug-01-23 10:00AM
Jul-24-23 08:00AM
Jul-18-23 02:58PM
Jun-20-23 08:00AM
Jun-08-23 11:14AM
May-31-23 08:00AM
May-24-23 07:33AM
May-22-23 04:30PM
May-17-23 10:16PM
May-16-23 07:00AM
May-11-23 08:39AM
May-02-23 04:35PM
May-01-23 07:00AM
01:07PM Loading…
Apr-25-23 01:07PM
Apr-13-23 04:30PM
Mar-31-23 07:00AM
Mar-16-23 07:00AM
Mar-14-23 07:14AM
Feb-28-23 08:00AM
Feb-19-23 10:53AM
Feb-17-23 06:43PM
Feb-06-23 12:00PM
Jan-31-23 09:40AM
Jan-09-23 07:00AM
Jan-05-23 08:00AM
Jan-03-23 05:40AM
Dec-30-22 09:03AM
Dec-23-22 09:40AM
Dec-13-22 11:41AM
Dec-12-22 01:37PM
Dec-08-22 07:00AM
Dec-07-22 09:55AM
Nov-22-22 08:00AM
Nov-16-22 11:26AM
Nov-10-22 07:00AM
Oct-11-22 10:06AM
Oct-06-22 08:00AM
Oct-05-22 06:26AM
Sep-26-22 08:00AM
Sep-10-22 07:00AM
Sep-06-22 08:00AM
Aug-29-22 01:58PM
Aug-11-22 07:00AM
Jun-09-22 12:00PM
May-25-22 03:10PM
May-18-22 12:49PM
May-17-22 08:00AM
May-12-22 07:00AM
May-02-22 04:30PM
Apr-15-22 08:03AM
Apr-06-22 08:00AM
Mar-17-22 07:00AM
Mar-04-22 02:34PM
Mar-01-22 08:00AM
Feb-28-22 08:00AM
Jan-11-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 10:00AM
Jan-03-22 08:00AM
Dec-14-21 07:00AM
Nov-09-21 04:30PM
Nov-03-21 09:15AM
Nov-01-21 07:05AM
Oct-17-21 09:06AM
Oct-15-21 04:30PM
Sep-28-21 08:00AM
Sep-27-21 11:55AM
Sep-07-21 08:00AM
Sep-02-21 08:00AM
Aug-18-21 08:57AM
Aug-05-21 07:30AM
Jul-25-21 06:20PM
Jul-19-21 02:05AM
Jun-28-21 08:00AM
May-27-21 08:00AM
May-03-21 01:17PM
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Binder GwendolynSee RemarksSep 19Option Exercise1.0111,00011,11031,000Sep 20 04:30 PM
Binder GwendolynSee RemarksSep 19Sale17.5711,000193,22020,000Sep 20 04:30 PM
Binder GwendolynSee RemarksAug 21Option Exercise1.0111,00011,11031,000Aug 22 04:30 PM
Binder GwendolynSee RemarksAug 21Sale13.4211,000147,58320,000Aug 22 04:30 PM
Binder GwendolynSee RemarksJul 19Option Exercise1.0111,00011,11031,000Jul 19 08:37 PM
Binder GwendolynSee RemarksJul 19Sale13.8211,000152,02220,000Jul 19 08:37 PM
Binder GwendolynSee RemarksJun 20Option Exercise1.0111,00011,11031,000Jun 21 04:38 PM
Binder GwendolynSee RemarksJun 20Sale12.9911,000142,92520,000Jun 21 04:38 PM
Binder GwendolynSee RemarksMay 19Option Exercise1.0122,00022,22042,000May 19 08:10 PM
Binder GwendolynSee RemarksMay 19Sale11.8122,000259,83320,000May 19 08:10 PM
Nichtberger StevenPresident & CEOOct 19Buy1.258,12710,152986,483Oct 19 08:19 PM
Nichtberger StevenPresident & CEOOct 18Buy0.99141,873141,008978,356Oct 18 09:50 PM
Simon MarkDirectorOct 18Buy0.98118,000115,286136,144Oct 18 09:50 PM
Marda AnupChief Financial OfficerOct 18Buy0.9950,00049,62050,000Oct 18 09:50 PM
Binder GwendolynSee RemarksOct 18Buy0.9920,00019,89420,000Oct 18 09:50 PM
Simon MarkDirectorOct 18Buy0.987,0006,8357,000Oct 18 09:50 PM
Bollard CatherineDirectorOct 18Buy0.991,0009941,000Oct 18 09:51 PM